Table 3 Perception of PrEP among HIV specialists according to their attitude towards PrEP prescription
From: Attitude towards antiretroviral pre-exposure prophylaxis (PrEP) prescription among HIV specialists
Positive | Negative | Total | OR (95% CI) | ||
|---|---|---|---|---|---|
216 | 95 | 311 | |||
I am concerned that PrEP will not be 100% effective (N = 295) | Agree | 161 (78.9) | 77 (84.6) | 238 | 1 |
Disagree | 43 (21.1) | 14 (15.4) | 57 | 1.47 (0.76-2.85) | |
I am concerned about the potential side effects of PrEP (N = 297) | Agree | 133 (64.9) | 75 (81.5) | 208 | 1 |
Disagree | 72 (35.1) | 17 (18.5) | 89 | 2.39 (1.31-4.35) | |
I feel uncomfortable prescribing drugs for new indications unless there is clear evidence of benefit (N = 293) | Agree | 132 (65.0) | 71 (78.9) | 203 | 1 |
Disagree | 71 (35.0) | 19 (21.1) | 90 | 2.01 (1.12-3.60) | |
I am concerned about a low adherence to PrEP* (N = 159) | Agree | 55 (59.8) | 44 (65.7) | 99 | 1 |
Disagree | 37 (40.2) | 23 (34.3) | 60 | 1.29 (0.67-2.48) | |
I do not have time to engage in prevention counselling and PrEP monitoring (N = 290) | Agree | 22 (11.0) | 7 (7.8) | 29 | 1 |
Disagree | 178 (89.0) | 83 (92.2) | 261 | 0.68 (0.28-1.66) | |
The use of PrEP will cause patients to engage in riskier behaviours (N = 297) | Agree | 145 (70.4) | 73 (80.2) | 218 | 1 |
Disagree | 61 (29.6) | 18 (19.8) | 79 | 1.71 (0.94-3.10) | |
The provision of PrEP will result in an increase in sexually transmitted disease incidence among patients (N = 296) | Agree | 136 (66.7) | 67 (72.8) | 203 | 1 |
Disagree | 68 (33.3) | 25 (27.2) | 93 | 1.34 (0.78-2.31) | |
Encourage access to testing and care for HIV infection are more effective measures* (N = 160) | Agree | 81 (87.1) | 64 (95.5) | 145 | 1 |
Disagree | 12 (12.9) | 3 (4.5) | 15 | 3.16 (0.86-11.68) | |
Non-biomedical HIV prevention interventions (behavioural) are more effective than PrEP (N = 290) | Agree | 136 (67.7) | 79 (88.8) | 215 | 1 |
Disagree | 65 (32.3) | 10 (11.2) | 75 | 3.78 (1.84-7.77) | |
Non-biomedical HIV prevention interventions (behavioural) are safer than PrEP (N = 301) | Agree | 183 (88.0) | 84 (90.3) | 267 | 1 |
Disagree | 25 (12.0) | 9 (9.7) | 34 | 1.28 (0.57-2.85) | |
The use of PrEP will result in less frequent HIV testing among patients (N = 299) | Agree | 90 (43.7) | 52 (55.9) | 142 | 1 |
Disagree | 116 (56.3) | 41 (44.1) | 157 | 1.63 (1.00-2.68) | |
PrEP is too costly (N = 295) | Agree | 159 (77.6) | 78 (86.7) | 237 | 1 |
Disagree | 46 (22.4) | 12 (13.3) | 58 | 1.88 (0.94-3.75) | |
The use of antiretrovirals for prevention will select for, and disseminate, antiretroviral drug resistance (N = 294) | Agree | 135 (66.5) | 68 (74.7) | 203 | 1 |
Disagree | 68 (33.5) | 23 (25.3) | 91 | 1.49 (0.85-2.60) | |